Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash & Equivalents: 2023-2024

Historic Cash & Equivalents for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $10.4 million.

  • BioLineRx's Cash & Equivalents fell 25.29% to $7.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.2 million, marking a year-over-year decrease of 25.29%. This contributed to the annual value of $10.4 million for FY2024, which is 145.26% up from last year.
  • As of FY2024, BioLineRx's Cash & Equivalents stood at $10.4 million, which was up 145.26% from $4.3 million recorded in FY2023.
  • BioLineRx's 5-year Cash & Equivalents high stood at $10.4 million for FY2024, and its period low was $4.3 million during FY2023.
  • Over the past 2 years, BioLineRx's median Cash & Equivalents value was $7.3 million (recorded in 2023), while the average stood at $7.3 million.
  • Data for BioLineRx's Cash & Equivalents shows a peak YoY spiked of 145.26% (in 2024) over the last 5 years.
  • BioLineRx's Cash & Equivalents (Yearly) stood at $4.3 million in 2023, then surged by 145.26% to $10.4 million in 2024.